Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NEXR vs AKAN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NEXR Captures Overall Composite Edge (31.0 SELL vs 43.8 HOLD), While AKAN Leads 4–1 on Growth & Valuation Pillars

NEXR Overall Winner 6-Pillar Tally: NEXR 1 – 4 AKAN (1 Tie) Matrix Metrics: NEXR 1 – 7 AKAN

As of Nov 16, 2026, NEXR (NEXR) captures the overall head-to-head institutional edge over Akanda Corp. Common Shares (AKAN) on higher Unified Composite conviction (31.0/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while AKAN wins 4–1 across the 6-pillar growth and valuation breakdown. NEXR trades at $1.38 (N/M Forward P/E, N/A operating margin) versus AKAN at $2.00 (N/M Forward P/E, -1254.5% operating margin).

  • Composite vs. Pillar Nuance: While AKAN currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. NEXR 31.0/100 SELL), NEXR captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (N/A vs. -1254.5% operating margin) and revenue trajectory (N/A vs. +21.9% YoY).
  • Technical & Structure Timing Caution: NEXR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 54.5); meanwhile AKAN is in a Breakdown options structure phase (RSI 66.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NEXR vs AKAN
NEXR US Equity Head-to-Head Winner
NEXR
Institutional Equity
$1.38
-7.38% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 8.42β · 2730% Vol
Unified Composite Score
31.0 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.5 · SMA20: $0.93 · SMA50: $1.16
AKAN NASDAQ
Akanda Corp. Common Shares
Medicinal Chemicals & Botanical Products
$2.00
+47.05% 1D
Market Cap $2.2M
TTM Revenue $662,469
Forward P/E N/M
Beta / 30D Vol 5.43β · 428% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 20.0 Fund 60.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 66
RSI-14: 66.4 · SMA20: $1.04 · SMA50: $1.86

6-Pillar Scorecard Institutional Category Breakdown (NEXR 1 – 4 AKAN)

Columns: Metric · NEXR · AKAN
1. Valuation Multiples AKAN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.3x
2. Growth & Scale AKAN
Revenue Growth (YoY) N/A +21.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $662,469
Market Cap N/A $2.2M
3. Profitability & Quality AKAN
Gross Margin N/A -12.0%
Operating Margin N/A -1254.5%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -60.9%
4. Balance Sheet & Cash Flow AKAN
Cash Generation (TTM) N/A -$7.9M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE -60.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NEXR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NEXR (1) vs AKAN (7)
Institutional Metric NEXR AKAN Criterion Row Edge
Market Capitalization
Scale
N/A $2.2M Larger Scale AKAN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +21.9% Higher Growth AKAN
Operating Margin (TTM)
Profitability
N/A -1254.5% Higher Margin AKAN
Net Profit Margin
Profitability
N/A 0.0% Higher Margin AKAN
Return on Equity (ROE)
Capital Efficiency
N/A -60.9% Higher ROE AKAN
52-Week Range Position
Momentum
23% ($0–$5) 2% ($0–$79) Stronger Trend NEXR
Beta / 30D Volatility
Risk Regime
8.42β · 2730% Vol 5.43β · 428% Vol Lower Realized Risk AKAN
Unified Institutional Score
Composite Signal
31.0 / 100 (SELL) 43.8 / 100 (HOLD) Higher Composite AKAN
Trailing 12M Revenue (USD)
Operating Scale
N/A $662,469 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -12.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$7.9M EBITDA (-60.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NEXR +0.61 pp
NEXR: +67.27% · AKAN: +66.66%
3M Horizon NEXR +11.12 pp
NEXR: -47.73% · AKAN: -58.85%
6M Horizon NEXR +88.46 pp
NEXR: +0.73% · AKAN: -87.73%
1Y Horizon AKAN +225.77 pp
NEXR: -39.21% · AKAN: +186.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NEXR vs AKAN. Trailing 12-month operating profitability (NEXR N/A vs AKAN -1254.5%) and valuation multiples (NEXR N/M vs AKAN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NEXR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
AKAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$662,469
Gross Margin-12.0%
Op. Margin-1254.5%
ROE / Fwd P/E-60.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NEXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NEXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKAN BREAKDOWN
137d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact AKAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NEXR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKAN Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.2M market capitalization and -1254.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NEXR vs AKAN Key Questions & Quantitative Answers

As of Nov 16, 2026, NEXR (NEXR) captures the overall head-to-head institutional edge over Akanda Corp. Common Shares (AKAN) on higher Unified Composite conviction (31.0/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while AKAN wins 4–1 across the 6-pillar growth and valuation breakdown. NEXR trades at $1.38 (N/M Forward P/E, N/A operating margin) versus AKAN at $2.00 (N/M Forward P/E, -1254.5% operating margin). Composite vs. Pillar Nuance: While AKAN currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. NEXR 31.0/100 SELL), NEXR captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (N/A vs. -1254.5% operating margin) and revenue trajectory (N/A vs. +21.9% YoY). Technical & Structure Timing Caution: NEXR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 54.5); meanwhile AKAN is in a Breakdown options structure phase (RSI 66.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AKAN leads the Growth & Scale pillar: NEXR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AKAN at +21.9% YoY revenue growth and +0.0% YoY earnings growth on $662,469 TTM revenue (-12.0% gross margin, -1254.5% operating margin). On trailing 12-month operating scale, NEXR generates N/A in USD-normalized revenue versus $662,469 for AKAN. In operating R&D and SG&A reinvestment, NEXR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKAN.

AKAN screens cheaper on headline valuation multiples. NEXR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AKAN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEXR (N/A ROE) versus AKAN (-60.9% ROE) capital efficiency.

In options market volatility and institutional positioning, NEXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.42β · 2730% Vol realized risk). By comparison, AKAN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (5.43β · 428% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.